Loading...
Loading...
Medgenics,
MDGN, today announced that
Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials
to assess the safety and efficacy of INFRADURE™ in patients with hepatitis C.
One study will evaluate previously untreated patients with genotypes 1 and 3,
and the other will study genotype 1 patients who have relapsed after initially
responding to prior treatments.
These are the first approved clinical studies for the use of INFRADURE, a
subcutaneous autologous tissue implant developed to continuously produce
interferon alpha (IFNa). INFRADURE has been designed to be used in treating
hepatitis B, C, and D, as well as other diseases. The first study will have up
to 16 patients with hepatitis C and is expected to start in the fourth quarter
of 2012 and to last approximately 24 months. The second study is planned to
commence following initial results of the first study.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in